Pfizer Signs a Research Collaboration and License Agreement with Dren Bio to Advance Multiple Therapeutic Antibodies for Cancer
Shots:
- Dren Bio to receive $25M up front & is eligible to receive $1B+ upon the achievement of development, regulatory, and commercial milestones along with royalties on net sales for each target-specific product
- The collaboration will use Dren Bio’s targeted myeloid engager and phagocytosis platform to develop therapeutic bispecific Abs for select oncology targets
- Pfizer gets the right to reserve & nominate additional oncology targets & will lead the development, manufacturing, regulatory, and commercialization activities while Dren Bio obtains an exclusive right globally for the platform including all other therapeutic targets which is currently in development
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com